• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
New diagnosis of multiple myeloma in a patient with mantle cell lymphoma: Shared genetic factors or simple coincidence?套细胞淋巴瘤患者新发多发性骨髓瘤：是共同的遗传因素还是单纯巧合？
Leuk Res Rep. 2012 Nov 10;1(1):7-8. doi: 10.1016/j.lrr.2012.09.003. eCollection 2012.
2
Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature.来那度胺联合卡非佐米和地塞米松治疗伴有 t(11,14)(q13;q32)的复发/难治性多发性骨髓瘤：两例病例报告及文献复习。
J Med Case Rep. 2020 Apr 23;14(1):54. doi: 10.1186/s13256-020-02376-y.
3
Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma.硼替佐米、来那度胺和地塞米松 upfront 方案与硼替佐米、环磷酰胺和地塞米松方案治疗多发性骨髓瘤的比较。
Eur J Haematol. 2019 Sep;103(3):247-254. doi: 10.1111/ejh.13280. Epub 2019 Jul 7.
4
Detection of t(12;14)(p13;q32) in a patient with IGH-CCND1 negative mantle cell lymphoma resembling ultra-high risk chronic lymphocytic leukemia.在一名IGH-CCND1阴性的套细胞淋巴瘤患者中检测到t(12;14)(p13;q32)，该患者类似超高危慢性淋巴细胞白血病。
Int J Clin Exp Pathol. 2015 Jun 1;8(6):7494-8. eCollection 2015.
5
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.自体造血干细胞移植对比硼替佐米-美法仑-泼尼松（联合或不联合硼替佐米-来那度胺-地塞米松巩固治疗）以及来那度胺维持治疗用于新诊断的多发性骨髓瘤（EMN02/HO95）：一项多中心、随机、开放标签的3期研究
Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.
6
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.硼替佐米联合来那度胺和地塞米松与单纯来那度胺和地塞米松治疗新诊断的无立即自体干细胞移植意向的骨髓瘤患者（SWOG S0777）：一项随机、开放标签的3期试验
Lancet. 2017 Feb 4;389(10068):519-527. doi: 10.1016/S0140-6736(16)31594-X. Epub 2016 Dec 23.
7
[A patient with mantle cell lymphoma who successfully underwent auto-PBSCT in combination with in vivo purging of tumor cells using rituximab].一名套细胞淋巴瘤患者成功接受了自体外周血干细胞移植，并联合使用利妥昔单抗进行体内肿瘤细胞清除。
Gan To Kagaku Ryoho. 2002 Dec;29(13):2569-72.
8
Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone.在接受包含硼替佐米、环磷酰胺和地塞米松的统一诱导方案治疗的多发性骨髓瘤患者中，不同干细胞动员方式后的植入情况比较。
Ann Hematol. 2017 Mar;96(3):461-467. doi: 10.1007/s00277-016-2897-2. Epub 2016 Dec 24.
9
Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines.在两条多发性骨髓瘤细胞系中，细胞周期蛋白D1通过易位至免疫球蛋白重链γ转换区而发生失调。
Blood. 1996 Jul 15;88(2):674-81.
10
Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.硼替佐米、来那度胺和地塞米松联合帕比司他用于适合移植的多发性骨髓瘤患者的一线治疗：一项1期试验。
Lancet Haematol. 2018 Dec;5(12):e628-e640. doi: 10.1016/S2352-3026(18)30174-1.

引用本文的文献

1
The Diagnostic and Treatment Challenges of Concomitant Mantle Cell Lymphoma and IgM Myeloma.套细胞淋巴瘤与IgM骨髓瘤并存的诊断与治疗挑战
Eur J Case Rep Intern Med. 2022 Jul 7;9(7):003463. doi: 10.12890/2022_003463. eCollection 2022.

本文引用的文献

1
Multiple myeloma.多发性骨髓瘤
N Engl J Med. 2011 Mar 17;364(11):1046-60. doi: 10.1056/NEJMra1011442.
2
Cyclin D1 inhibits mitochondrial activity in B cells.周期蛋白 D1 抑制 B 细胞中的线粒体活性。
Cancer Res. 2011 Mar 1;71(5):1690-9. doi: 10.1158/0008-5472.CAN-10-2564. Epub 2011 Feb 22.
3
Molecular characteristics of mantle cell lymphoma presenting with clonal plasma cell component.具有克隆性浆细胞成分的套细胞淋巴瘤的分子特征。
Am J Surg Pathol. 2011 Feb;35(2):177-89. doi: 10.1097/PAS.0b013e3182049a9c.
4
Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.套细胞淋巴瘤：在基因组时代的生物学、发病机制和治疗的分子基础。
Blood. 2011 Jan 6;117(1):26-38. doi: 10.1182/blood-2010-04-189977. Epub 2010 Oct 12.
5
Cyclin K and cyclin D1b are oncogenic in myeloma cells.细胞周期蛋白 K 和 D1b 在骨髓瘤细胞中致癌。
Mol Cancer. 2010 May 10;9:103. doi: 10.1186/1476-4598-9-103.
6
Mantle cell lymphoma arising in a multiple myeloma patient responding to lenalidomide.来那度胺治疗有效的多发性骨髓瘤患者发生套细胞淋巴瘤。
Leuk Res. 2010 Jul;34(7):e178-80. doi: 10.1016/j.leukres.2010.01.002. Epub 2010 Jan 15.
7
A myeloma translocation-like model associating CCND1 with the immunoglobulin heavy-chain locus 3' enhancers does not promote by itself B-cell malignancies.一种与免疫球蛋白重链基因座 3'增强子相关的骨髓瘤易位样模型本身并不能促进 B 细胞恶性肿瘤。
Leuk Res. 2010 Aug;34(8):1043-51. doi: 10.1016/j.leukres.2009.11.017.
8
A 3-way collision tumor of the upper respiratory tract: a composite of 2 immunophenotypically distinct mantle cell lymphomas and a plasmacytoma.上呼吸道三向碰撞肿瘤：由两种免疫表型不同的套细胞淋巴瘤和一个浆细胞瘤组成的复合瘤。
Hum Pathol. 2008 May;39(5):781-7. doi: 10.1016/j.humpath.2007.08.023. Epub 2008 Mar 4.
9
Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma.在小鼠淋巴细胞中组成型核细胞周期蛋白D1的表达会诱发B细胞淋巴瘤。
Oncogene. 2006 Feb 16;25(7):998-1007. doi: 10.1038/sj.onc.1209147.
10
Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways.套细胞淋巴瘤的发病机制：所有致癌途径均导致细胞周期和DNA损伤反应通路失调。
J Clin Oncol. 2005 Sep 10;23(26):6364-9. doi: 10.1200/JCO.2005.05.019.

套细胞淋巴瘤患者新发多发性骨髓瘤：是共同的遗传因素还是单纯巧合？

New diagnosis of multiple myeloma in a patient with mantle cell lymphoma: Shared genetic factors or simple coincidence?

作者信息

Sikuyayenga Mutende J, Reeder Craig B, Mikhael Joseph R

机构信息

Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ, United States.

出版信息

Leuk Res Rep. 2012 Nov 10;1(1):7-8. doi: 10.1016/j.lrr.2012.09.003. eCollection 2012.

DOI:10.1016/j.lrr.2012.09.003
PMID:24371760
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3787821/
Abstract

Multiple Myeloma and Mantle Cell Lymphoma are well defined hematological malignancies. Understanding of their pathogeneses has led to new therapies and increased survival. We report on a 64-yr-old female who was diagnosed with mantle cell lymphoma in 2003, then multiple myeloma in 2010. We identified only few other cases of concomitant MM and MCL. We also explored the importance of t(11;14)(q13;q32). The development of these two disorders in the same patient may simply be due to chance; however, it may also represent a common genetic hit affecting the B-cell population leading to development of two different malignancies.

摘要

多发性骨髓瘤和套细胞淋巴瘤是明确的血液系统恶性肿瘤。对其发病机制的了解带来了新的治疗方法并提高了生存率。我们报告了一名64岁女性，她于2003年被诊断为套细胞淋巴瘤，2010年又被诊断为多发性骨髓瘤。我们仅发现了其他少数几例同时患有多发性骨髓瘤和套细胞淋巴瘤的病例。我们还探讨了t(11;14)(q13;q32)的重要性。这两种疾病在同一患者体内的发生可能仅仅是偶然；然而，它也可能代表一种影响B细胞群体的共同基因打击，导致两种不同恶性肿瘤的发生。